Clinical significance of serum decoy receptor 3 levels in patients with systemic sclerosis

Daisuke Yamada, Yoshihide Asano, Takehiro Takahashi, Yuri Masui, Naohiko Aozasa, Kaname Akamata, Shinji Noda, Zenshiro Tamaki, Yayoi Tada, Makoto Sugaya, Shinichi Sato, Takafumi Kadono

研究成果: ジャーナルへの寄稿学術論文査読

10 被引用数 (Scopus)


Decoy receptor 3 (DcR3) is associated with autoimmunity and altered angiogenesis in certain pathological conditions. We herein measured serum DcR3 levels in 51 patients with systemic sclerosis (SSc) and 19 healthy controls and evaluated their clinical significance in this disorder. Serum DcR3 levels were significantly higher in diffuse cutaneous SSc (dcSSc) patients than in limited cutaneous SSc patients and in healthy controls. In dcSSc, serum DcR3 levels were significantly elevated inpatients with disease durationof ≤6 years compared with healthy controls, but not in those with disease duration of >6 years. Serum DcR3 levels correlated negatively with the percentage of predicted diffusion lung capacity for carbon monoxide and positively with right ventricular systolic pressure. Furthermore, serum DcR3 levels positively correlated with C-reactive protein, erythrocyte sedimentation rate and immunoglobulin G. Collectively, the elevation of serum DcR3 levels is associated with the development of pulmonary arterial hypertension and systemic inflammation in SSc.

ジャーナルEuropean Journal of Dermatology
出版ステータス出版済み - 2012 5月


「Clinical significance of serum decoy receptor 3 levels in patients with systemic sclerosis」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。